CASI PHARMACEUTICALS (CASIF) Stock News

CASI Pharmaceuticals (OTCQB: CASIF) reported first half 2026 results and clinical, corporate, and listing developments. Revenue was $9.8 million, down 5.8% year over year, while gross profit rose to $7.7 million. Net loss narrowed to $20.0 million from $24.1 million. Operating expenses decreased in research and development and selling and marketing but increased in general and administrative, partly from higher legal fees. CASI completed a $15 million related-party convertible note financing, received a favorable arbitration award exceeding RMB 100 million in the Juventas dispute, and restored the EVOMELA license via settlement with Acrotech. The company advanced CID-103 with first patient dosed in an AMR Phase 1/2 trial in China and completion of Part A enrollment in an ITP Phase 1/2 study. CASI was delisted from Nasdaq in February 2026; its shares began OTCQB quotation as CASIF in April.